2021 Refresher - Central Nervous System
The barriers to improving and changing practice are due to the rapidly evolving pace of high-level data in the treatment of brain tumors. As novel approaches are explored, further study is called for to provide more granular guidance into which patients may benefit. In metastatic cancer to the brain there is evolving data on novel treatment techniques, in sequencing, and the addition of systemic therapies. In primary brain tumor, pathologic analysis is becoming increasingly molecular and is leading to our rethinking about glioma classification, and thus how we recommend therapies. The failure to stay apprised to these changes and apply to daily practice will lead to poor treatment outcomes and increased toxicities.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, nurses, radiation dosimetrists and radiation oncology residents.
Upon completion of this live activity, attendees should be able to:
- Determine when RT is appropriate for meningioma, and describe the pathologic and radiographic features to determine the CTV, and what the likely toxicity profile is.
- Weigh the risks and benefits are for PCI and therapy for metastatic small cell lung cancer to the brain.
- Apply the evidence for SRS to intact and resected brain metastases.
Stephanie Weiss, MD is employed by Fox Chase Cancer Center and has financial interest from Astra Zeneca and Regeneron.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.